Bristol, Ambrx team up to develop antibody-based cancer drugs

05/6/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Ambrx agreed to co-develop antibody drug conjugates for cancer with the latter's protein medicinal technology. Ambrx will receive $15 million upfront and as much as $97 million in research funding and milestone fees for each product, plus sales royalties. Bristol will get the global rights to develop and market the drugs arising from the partnership.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN